文献速递外周动脉疾病

紫杉醇涂层器械血运重建治疗慢性肢体威胁性缺血患者的结局

Outcome after revascularization with paclitaxel-coated devices in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2023-02-06

该回顾性队列研究基于血管质量倡议外周血管干预数据库2016至2020年数据,经倾向评分匹配比较紫杉醇涂层与非涂层器械治疗股腘动脉病变的慢性肢体威胁性缺血患者。匹配后各14065例,紫杉醇组18个月保肢率、一期通畅率及无主要不良肢体事件率均更高,主要截肢、一期通畅丧失及主要不良肢体事件风险更低,54个月全因生存率总体无统计学差异。

要点

  • 匹配后紫杉醇组18个月保肢率89.2% vs 非紫杉醇组86.5%,P < .001
  • 紫杉醇组主要截肢风险更低(HR 0.74;95%CI 0.67-0.82;P < .001)
  • 54个月全因生存率两组无统计学差异(73.5% vs 71.3%;P = .07)

核心结论

  • 股腘动脉干预使用紫杉醇涂层器械在18个月随访时与非涂层器械相比与更高的保肢率、一期通畅率和无主要不良肢体事件率相关。
  • 该获益在至4.5年随访时未伴随全因死亡率的增加。
  • 需要进一步研究以确定紫杉醇在慢性肢体威胁性缺血患者股腘动脉治疗中的最佳角色并了解其长期结局。

研究设计与样本

  • 回顾性研究,纳入血管质量倡议外周血管干预数据库中2016至2020年因慢性肢体威胁性缺血指征接受股腘动脉干预的患者,包括同期行髂动脉或胫动脉干预者,每例患者研究一条肢体。
  • 基于人口学、合并症、指征和药物治疗进行倾向评分匹配生成均衡队列,共匹配紫杉醇组14065例与非紫杉醇组14065例。
  • 采用Kaplan-Meier生存分析和多因素Cox回归比较保肢、总体生存、一期通畅和主要不良肢体事件。

主要发现

  • 匹配后紫杉醇组与非紫杉醇组人口学、合并症、指征和手术细节相似。
  • 18个月随访Kaplan-Meier分析显示紫杉醇组较非紫杉醇组保肢率更高(89.2% vs 86.5%;P < .001)、一期通畅率更高(80.3% vs 76.9%;P < .001)、无主要不良肢体事件率更高(72.6% vs 67.9%;P < .001)。
  • 多因素分析显示紫杉醇治疗与更低的主要截肢风险(HR 0.74;95%CI 0.67-0.82;P < .001)、一期通畅丧失风险(HR 0.80;95%CI 0.74-0.87;P < .001)和主要不良肢体事件风险(HR 0.77;95%CI 0.72-0.82;P < .001)相关。
  • 总体21%的患者有同侧外周血管干预史,剔除这些患者后18个月结果相似。
  • 总体队列54个月总体生存率紫杉醇组与非紫杉醇组无统计学差异(73.5% vs 71.3%;P = .07),但在新发治疗患者中有统计学差异(73.9% vs 70.7%;P = .02);多因素分析显示紫杉醇组死亡风险更低(HR 0.93;95%CI 0.87-0.98;P = .02)。

局限性

  • 原文结论指出需要进一步研究以确定紫杉醇在慢性肢体威胁性缺血患者股腘动脉治疗中的最佳角色并了解其长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Data regarding the safety and efficacy of paclitaxel (PTX)-coated peripheral arterial devices for femoropopliteal artery (FPA) atherosclerotic disease is derived from studies that mainly evaluated patients with claudication. Outcomes of PTX treatment for patients with chronic limb-threatening ischemia (CLTI) is incompletely defined. This study compares outcome in patients with CLTI treated with and without PTX. METHODS: We retrospectively studied patients who underwent FPA intervention for an indication of CLTI in the Vascular Quality Initiative peripheral vascular intervention database from 2016 to 2020. Patients who had concomitant iliac or tibial interventions were included. One limb per patient was studied. Propensity score matching based on demographics, comorbidities, indication, and pharmacological therapy was performed to generate balanced cohorts. Kaplan-Meier survival analysis and multivariate Cox regression compared limb salvage, overall survival, primary patency, and major adverse limb events (MALE) between patients treated with and without PTX. RESULTS: Demographics, comorbidities, indications, and procedural details were similar between 14,065 PTX and 14,065 non-PTX propensity-matched patients. Kaplan-Meier analysis at 18-month follow-up demonstrated that the PTX group compared with the non-PTX group had a significantly higher rates of limb salvage (89.2% vs 86.5%; P < .001), primary patency (80.3% vs 76.9%; P < .001), and freedom from MALE (72.6% vs 67.9%; P < .001). Multivariate analysis also showed that PTX treatment was associated with a lower risk of major amputation (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.67-0.82; P < .001), loss of primary patency (HR, 0.80; 95% CI, 0.74-0.87; P < .001), and MALE (HR, 0.77; 95% CI, 0.72-0.82; P < .001). Overall, 21% of patients had a prior ipsilateral peripheral vascular intervention. Removing these patients from the analysis yielded similar results at 18 months. Overall survival at 54 months was not statistically different between the PTX and non-PTX groups in the overall cohort (73.5 vs 71.3%; P = .07), but significant in the de-novo treated patients (73.9% vs 70.7%; P = .02).Multivariate analyses showed a lower mortality risk in the PTX patients (HR, 0.93; 95% CI, 0.87-0.98; P = .02). CONCLUSIONS: FPA intervention with a PTX-coated device is associated with improved limb salvage, primary patency, and freedom from MALE at the 18-month follow-up compared with uncoated devices. This benefit was not associated with an increase in all-cause mortality out to 4.5 years. Further study is necessary to determine the optimal role for PTX in the treatment of the FPA for patients with CLTI and to understand its long-term outcome.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Smith JA, So KL, Kashyap VS, et al. Outcome after revascularization with paclitaxel-coated devices in patients with chronic limb-threatening ischemia. J Vasc Surg. 2023. PMID: 36754247. doi:10.1016/j.jvs.2023.01.195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。